Display options
Cite
Mukomolov S, Trifonova G, Levakova I, et al. Hepatitis C in the Russian Federation: challenges and future directions. Hepat Med. 2016;8:51-60doi: 10.2147/HMER.S50172.
Mukomolov, S., Trifonova, G., Levakova, I., Bolsun, D., & Krivanogova, E. (2016). Hepatitis C in the Russian Federation: challenges and future directions. Hepatic medicine : evidence and research, 851-60. https://doi.org/10.2147/HMER.S50172
Mukomolov, Sergey, et al. "Hepatitis C in the Russian Federation: challenges and future directions." Hepatic medicine : evidence and research vol. 8 (2016): 51-60. doi: https://doi.org/10.2147/HMER.S50172
Mukomolov S, Trifonova G, Levakova I, Bolsun D, Krivanogova E. Hepatitis C in the Russian Federation: challenges and future directions. Hepat Med. 2016 May 05;8:51-60. doi: 10.2147/HMER.S50172. eCollection 2016. PMID: 27217802; PMCID: PMC4861609.
Copy Download .nbib Format: NLM
Share it on

Hepat Med. 2016 May 05;8:51-60. doi: 10.2147/HMER.S50172. eCollection 2016.

Hepatitis C in the Russian Federation: challenges and future directions.

Hepatic medicine : evidence and research

Sergey Mukomolov, Galina Trifonova, Irina Levakova, Daria Bolsun, Eugenia Krivanogova

Affiliations

  1. Department of Epidemiology, Saint-Petersburg Pasteur Institute, Saint Petersburg, the Russian Federation.

PMID: 27217802 PMCID: PMC4861609 DOI: 10.2147/HMER.S50172

Abstract

Hepatitis C virus (HCV) infection is one of the most prevalent health problems in the world. Official registration of HCV infections in the Russian Federation started in 1994. Two clinical forms of infection - acute and chronic hepatitis C - are registered separately. Moreover, the HCV national surveillance system also includes reports from laboratories on results from testing ∼20 population risk groups for antibodies to HCV; approximately 15-16 million tests are performed annually. Modern epidemiological features of HCV infection in the Russian Federation are characterized by low incidence of the acute form of infection (acute HCV; one to two per 100,000) and a dramatic increase in chronic HCV (CHCV) cases. In 2013, the average nationwide rate of newly detected CHCV cases was 39.3/100,000. In the same year, the prevalence of CHCV demonstrating an accumulation of chronically infected patients in the country was much higher - 335.8/100,000. Four risk groups were identified as greatly affected by HCV, which were demonstrated by a high prevalence of antibodies to HCV: newborns from chronically infected women, persons from correctional facilities, patients with chronic liver diseases, and clients from clinics for sexually transmitted disease patients and drug users. It was found that several HCV genotypes circulated in different regions of the country; HCV1b had a prevalence of 55%-80% in almost every part of the country. However, in St Petersburg during the final decade of the last century and from 2001-2005, HCV3a subtype expanded circulation among young people due to increased intravenous drug addiction. Intravenous drug users were the major cause of a higher registration of double infection, with two different virus subtypes, and the appearance in Russia of new recombinant virus RF_2k/1b. It can be concluded that CHCV infection should be a focus of the health care system in Russia because serious epidemics of liver cirrhosis and hepatocellular carcinoma will be seen in the near future that will require urgent preventive and therapeutic measures.

Keywords: chronic hepatitis C; epidemiology; hepatitis C; the Russian Federation

References

  1. Hepatol Res. 2008 May;38(5):457-64 - PubMed
  2. J Med Virol. 2007 Apr;79(4):374-82 - PubMed
  3. Addiction. 2009 Nov;104(11):1881-90 - PubMed
  4. J Clin Microbiol. 2005 Jun;43(6):2810-5 - PubMed
  5. J Med Virol. 2009 Feb;81(2):238-48 - PubMed
  6. Science. 1989 Apr 21;244(4902):359-62 - PubMed
  7. J Med Virol. 1997 Sep;53(1):36-40 - PubMed
  8. J Med Virol. 2001 Nov;65(3):517-24 - PubMed
  9. Arch Virol. 1996;141(9):1613-22 - PubMed
  10. J Virol. 2002 Apr;76(8):4034-43 - PubMed
  11. J Med Virol. 2013 May;85(5):815-22 - PubMed

Publication Types